Springworks Therapeutics Inc (SWTX) Stock Price, Quote & News

Company Profile

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neu...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 883 9490

Website: www.springworkstx.com

Address:

100 Washington Boulevard, Stamford, United States

LmFaA Jul. 9 at 1:13 PM

$SWTX aaand it is over. -15% mainly due to bad $/€, oh well

0 · Reply

WAJeff Jul. 9 at 12:18 PM

$MRK This was less than I expected for $VRNA (I would have expected $120+) but not quite the highway robbery purchase price in $SWTX. Merck should be up on this too.

0 · Reply

kareem4king Jul. 7 at 2:40 AM

$AXSM $IRWD $SWTX $TNXP

0 · Reply

Ivan2500 Jul. 6 at 9:50 AM

$TNXP has a commercial team already in place—both U.S. and international strategy underway. With a market cap of just $277M, it's severely undervalued vs. peers: $AXSM: $3.5B (1 drug approved) $IRWD: $1.9B $SWTX: $2.5B Post-FDA approval, $TNXP could become a mid-cap ($2B–$4B) biotech. That’s a 7x–12x upside from current levels.

4 · Reply

Longterm_Inv Jul. 1 at 3:14 PM

$SWTX https://www.investing.com/news/sec-filings/merck-kgaa-completes-acquisition-of-springworks-therapeutics-for-47-per-share-93CH-4119394

0 · Reply

TwongStocks Jun. 27 at 7:41 PM

$SWTX NASDAQ Equity Corporate Actions Alert #2025 - 337 Information Regarding the Merger of SpringWorks Therapeutics, Inc. (SWTX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-337 At a special meeting held on June 26, 2025, the shareholders of SpringWorks Therapeutics, Inc. (SWTX) approved the proposed merger with Merck KGaA. The merger is tentatively scheduled to close prior to the market open on July 1, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on June 30, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (July 1st) and will be suspended effective July 2, 2025. Merger consideration is $47.00 for each share of SWTX.

1 · Reply

TheNewMochaJoe Jun. 26 at 8:30 PM

$ALT Historical Precedent For Buyout Recent comparable transactions: Intercept Pharma ($ICPT) acquired by Alfasigma for $794M after mixed NASH data Akero ($AKRO) had big-pharma M&A speculation after Phase 2a/2b readouts SpringWorks ($SWTX) bought by Merck KGaA after positive Phase 2 Altimmune's current market cap is under $200M after the selloff — that’s low-risk optionality for pharma if the 48-week data confirms durability.

4 · Reply

flanker30 Jun. 26 at 3:49 PM

$ALT burnt in $ALT , $SWTX as well as $IOVA, thats a bad bad track record. Only one that saves is $TGTX 🤞

1 · Reply

patten1962 Jun. 25 at 8:17 PM

$SWTX Open interest is now 118k Contracts. @Afterbell @MaxDanger

0 · Reply

raticals Jun. 20 at 4:27 PM

$SWTX traded a couple cents above deal price today. Very weird

0 · Reply

Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business

Jun 20, 2025, 8:00 AM EDT - 26 days ago

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

Jun 3, 2025, 5:43 PM EDT - 6 weeks ago

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

May 23, 2025, 8:00 AM EDT - 7 weeks ago

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

Apr 28, 2025, 5:33 PM EDT - 2 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

Apr 28, 2025, 7:25 AM EDT - 2 months ago

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

Apr 28, 2025, 2:33 AM EDT - 2 months ago

Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal

Apr 28, 2025, 2:21 AM EDT - 2 months ago

Germany's Merck KGaA in $3.9 bln deal to acquire US biotech firm SpringWorks

Apr 28, 2025, 2:13 AM EDT - 2 months ago

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Apr 28, 2025, 2:11 AM EDT - 2 months ago

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Apr 27, 2025, 10:35 AM EDT - 2 months ago

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

Apr 24, 2025, 3:20 PM EDT - 2 months ago

Germany's Merck nears roughly $3.5 billion deal for SpringWorks, WSJ reports

Apr 24, 2025, 3:05 PM EDT - 2 months ago

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks

Mar 27, 2025, 7:40 AM EDT - 3 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI GPCR INSM MRK

Mar 11, 2025, 9:15 AM EDT - 4 months ago

SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz

Feb 20, 2025, 3:50 PM EST - 5 months ago

Top 3 Health Care Stocks You May Want To Dump In February

LUNG MD

Feb 20, 2025, 6:30 AM EST - 5 months ago

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 19, 2025, 8:00 AM EST - 5 months ago

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

Feb 17, 2025, 4:05 PM EST - 5 months ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics

Feb 11, 2025, 8:20 PM EST - 5 months ago

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Feb 11, 2025, 5:27 PM EST - 5 months ago

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Feb 11, 2025, 3:59 PM EST - 5 months ago

US FDA approves Springworks' genetic disorder drug

Jan 30, 2025, 7:00 AM EST - 5 months ago

SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

Jan 13, 2025, 6:30 AM EST - 6 months ago

SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 5:56 AM EST - 6 months ago

SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate

Jan 3, 2025, 6:30 AM EST - 6 months ago

SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 31, 2024, 8:30 AM EST - 7 months ago

SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great

Dec 15, 2024, 2:00 PM EST - 7 months ago

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

TARS

Nov 26, 2024, 7:00 AM EST - 8 months ago

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 1:20 PM EST - 8 months ago

SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 9:25 AM EST - 8 months ago

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 12, 2024, 6:30 AM EST - 8 months ago

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 11, 2024, 7:00 AM EST - 8 months ago

SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

Nov 11, 2024, 6:30 AM EST - 8 months ago

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

Nov 7, 2024, 6:30 AM EST - 8 months ago

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

Nov 5, 2024, 7:00 AM EST - 9 months ago

SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 4, 2024, 12:17 PM EST - 9 months ago

SpringWorks Therapeutics Merits A Speculative Buy

Oct 22, 2024, 7:00 AM EDT - 9 months ago

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Aug 28, 2024, 6:30 AM EDT - 11 months ago

FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

Aug 9, 2024, 9:09 AM EDT - 1 year ago

SpringWorks Therapeutics Recent Developments Move This To Speculative Buy (Upgrade)

Aug 7, 2024, 5:46 PM EDT - 1 year ago

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Aug 7, 2024, 1:08 PM EDT - 1 year ago

SpringWorks Therapeutics, Inc. (SWTX) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 6:30 AM EDT - 1 year ago

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 29, 2024, 6:30 AM EDT - 1 year ago

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

Jul 2, 2024, 12:49 PM EDT - 1 year ago

Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm

Jul 1, 2024, 6:30 AM EDT - 1 year ago

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Jun 5, 2024, 7:00 AM EDT - 1 year ago

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

LmFaA Jul. 9 at 1:13 PM

$SWTX aaand it is over. -15% mainly due to bad $/€, oh well

0 · Reply

WAJeff Jul. 9 at 12:18 PM

$MRK This was less than I expected for $VRNA (I would have expected $120+) but not quite the highway robbery purchase price in $SWTX. Merck should be up on this too.

0 · Reply

kareem4king Jul. 7 at 2:40 AM

$AXSM $IRWD $SWTX $TNXP

0 · Reply

Ivan2500 Jul. 6 at 9:50 AM

4 · Reply

Longterm_Inv Jul. 1 at 3:14 PM

$SWTX https://www.investing.com/news/sec-filings/merck-kgaa-completes-acquisition-of-springworks-therapeutics-for-47-per-share-93CH-4119394

0 · Reply

TwongStocks Jun. 27 at 7:41 PM

1 · Reply

TheNewMochaJoe Jun. 26 at 8:30 PM

4 · Reply

flanker30 Jun. 26 at 3:49 PM

$ALT burnt in $ALT , $SWTX as well as $IOVA, thats a bad bad track record. Only one that saves is $TGTX 🤞

1 · Reply

patten1962 Jun. 25 at 8:17 PM

$SWTX Open interest is now 118k Contracts. @Afterbell @MaxDanger

0 · Reply

raticals Jun. 20 at 4:27 PM

$SWTX traded a couple cents above deal price today. Very weird

0 · Reply

Wallst45 Jun. 20 at 1:24 AM

$MDGL $SWTX Merck KGaA deal was also contingent on CHMP opinion. So no wonder deal is already in works and just awaiting CHMP opinion

0 · Reply

Ccg_ Jun. 19 at 12:35 PM

$SWTX did shareholder vote occur? Was it passed?

0 · Reply

patten1962 Jun. 19 at 11:55 AM

$SWTX Open intrest is now up to 113k shares. I have 200 calls. I am well aware i will probably lose all of it. I just find it strange. @Afterbell @MaxDanger

0 · Reply

Mergerbrief Jun. 13 at 11:04 AM

$SWTX / $MRK - $HSR Possible Expiration

0 · Reply

patten1962 Jun. 6 at 10:55 PM

$SWTX This is interesting. @MaxDanger @rooksleanne @Afterbell

0 · Reply

patten1962 Jun. 5 at 7:30 PM

$SWTX Just sold the last of my shares. Now i just hold a few of those stupid July $50 calls.

0 · Reply

zmanx Jun. 3 at 9:48 PM

$SWTX closed out full position here today — has a BO offer for $47 so will be out a few pennies but whatever— was a great pay off from initial buy as well… onto the next

0 · Reply

patten1962 Jun. 3 at 10:18 AM

$SWTX DO NOT VOTE FOR THIS DEAL!

1 · Reply

CrispDry Jun. 2 at 3:22 PM

$VRNA overall all of this years buyouts are coming in “under value”. $SWTX $BPMC

0 · Reply

raticals May. 30 at 2:34 PM

$SWTX during the buyout process bankers reached out to 8 counterparties for interest in the company. All passed. Wonder why as it seems this will be money machine in future

1 · Reply

BioRich May. 30 at 3:01 AM

$SWTX Voting against this ridiculous merger. Most insanely low BO offer. Absolutely terrible. What's the angle here?

2 · Reply

Longterm_Inv May. 29 at 5:38 PM

$SWTX Happily voted AGAINST on Plan of Merger, Adjournment, and Executive Compensation.

0 · Reply

Market Cap	3.54B
Revenue (ttm)	191.59M
Net Income (ttm)	-258.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-134.73%
Debt to Equity Ratio	0.00

Volume	5,010,800
Avg Vol	6,589,954
Day's Range	N/A - N/A
Shares Out	75.35M
Stochastic %K	89%
Beta	0.70
Analysts	Sell
Price Target	$52.28